Valeant Pharmaceuticals International
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 20, 2008
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction of
incorporation or organization) 		  1-11397
(Commission File Number) 		  33-0628076
(IRS Employer
Identification No.)
     
One Enterprise
Aliso Viejo, California
(Address of principal executive offices) 		  92656
(Zip Code)
Registrant’s telephone number, including area code: (949) 461-6000
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01 Financial Statements and Exhibits
SIGNATURES
EXHIBIT 3.1

Table of Contents

Item 5.03   Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
(a) On February 20, 2008, our Board of Directors amended Article V, Sections 1, 3 and 4 of our Amended and Restated Bylaws, effective immediately, to allow for the issuance of uncertificated shares of our capital stock to be eligible for a direct registration system whereby shares are uncertificated and represented by electronic record.
The summary of the changes to the terms of our Amended and Restated Bylaws as set forth in this Item 5.03 is subject and qualified in its entirety by our Amended and Restated Bylaws, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated by reference herein.
Item 9.01   Financial Statements and Exhibits.
(d) Exhibits.
     
Exhibit    
Number   Exhibit Description
3.1
  Amended and Restated Bylaws

2.

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Valeant Pharmaceuticals International
 		  
Date: February 25, 2008  By:   /s/ Eileen C. Pruette    
           Eileen C. Pruette   
           Executive Vice President, General Counsel   
 

3.

Table of Contents

EXHIBIT INDEX
     
Exhibit No.   Description
3.1
  Amended and Restated Bylaws